SGLT2 transporter protein inhibitor improves glycaemic control in adult patients with type 2 diabetes mellitus.


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Forxiga (dapagliflozin), a novel treatment for type 2 diabetes mellitus.

Posted on the EMA website, 20 April 2012